Primary Antibodies  >  Infectious Disease Antibodies
 

H5N1 Antibody VN04-8

Mouse Monoclonal 3G2 IgG1 kappa
NCI Collaboration JCYIA Product
Order Offline
  • H5N1 Antibody VN04-8
  • H5N1 Antibody VN04-8
Number:
200-301-976
Size:
100 µg
Price:
$329.00
Shipping:
$41.00
Handling:
$20.00
Availability:
Ships next business day.

H5N1 Antibody VN04-8 Properties

Description
H5N1 Antibody (VN04-8) - 200-301-976
Host
Mouse
Target Species
H5N1 virus
Known Cross Reactivity
virus
Clonality
Monoclonal 3G2 IgG1 kappa
Application
ELISA : 1:5,000
Neutralization : User Optimized
Western Blot : User Optimized
Immunohistochemistry: User Optimized
ImmunoPrecipitation: User Optimized
Physical State
Liquid (sterile filtered)
Shipping Condition
Dry Ice
Format
IgG1
Label
Unconjugated
Concentration
1.0 mg/mL by UV absorbance at 280 nm
Buffer
0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative
0.01% (w/v) Sodium Azide
Stabilizer
None
GeneName
HA
Download CofA:
Lot#  
Print

H5N1 Antibody VN04-8 Description

Background
Hemagglutinin of A/Vietnam/1203/04 Influenza Virus (VN04-8) Antibody raised against the hemagglutinin (HA) surface glycoprotein of the A/Vietnam/1203/04 (H5N1) influenza virus. Generally referred to as ''bird flu'', the H5N1 influenza A virus has been documented in poultry and humans across ten Eurasian countries, from Japan in the north to Indonesia in the south. Without immunity, humans would have no protection against H5N1 influenza viruses, which could potentially cause a catastrophic pandemic influenza.  This antibody, directed against the HA surface glycoprotein of the A/Vietnam/1203/04 (H5N1) influenza virus, is intended to further our understanding of the mechanisms underlying antigenic variation and evolution of novel variants. The major functions of HA include receptor-binding and fusion activities, but there may also be a structural role for HA in viral particle formation. Following attachment of HA to surface receptors on susceptible cells, the influenza virus enters the cell via endocytosis and membrane fusion.
Synonyms
H5HA antibody, Hemagglutinin 5 antibody, H5N1 antibody
Immunogen
Hemagglutinin of A/Vietnam/1203/04 Influenza Virus (VN04-8) monoclonal antibody was produced by intraperitoneal immunization of BALB/c mice with concentrated purified virus preparation containing hemagglutinin (HA) protein of influenza A virus [strain A/Vietnam/1203/04 (H5N1)] using the modification of the method described by Kohler and Milstein. Each mouse received two immunizations of 15 µg HA with incomplete Freund’s adjuvant, administered 3 week apart.
Immunogen Type
Native Protein
Storage Condition
Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Application Note
Hemagglutinin of A/Vietnam/1203/04 Influenza Virus (VN04-8) monoclonal antibody can be used for hemagglutination inhibition (HI) assays to provide antigenic characterization of the influenza A viruses of the H5 HA subtype. This monoclonal antibody is suitable for virus neutralization assays (in cell culture and in embryonated chicken eggs), ELISA, immunoprecipitation, immunohistochemistry and western blotting.
Purity/Specifity
This product was purified from tissue culture supernatant fluid by Protein A chromatography and is specific for H5 hemagglutinin (HA) protein of influenza A virus [strain A/Vietnam/1203/04 (H5N1)].  VN04-8 monoclonal antibody did not cross-react with influenza viruses of other HA subtypes. This monoclonal antibody reacted with H5N1 influenza viruses representatives of different clades and subclades of the H5 HA subtype.
Disclaimer Note-General
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
General Reference
Guan, Y., et al. (2004) H5N1 Influenza: A Protean Pandemic Threat. Proc. Natl. Acad. Sci. U.S.A. 101: 8156–8161. Li, K. S., et al. (2004) Genesis of a Highly Pathogenic and Potentially Pandemic H5N1 Influenza Virus in Eastern Asia. Nature 430: 209–213. Stevens, J., et al. (2006) Structure and Receptor Specificity of the Hemagglutinin from an H5N1 Influenza Virus. Science 312: 404–410. Hatta, M., et al.  (2001) Molecular Basis for High Virulence of Hong Kong H5N1 Influenza A Viruses. Science 293: 1840–1842. Webster, R.G., et al. (1980) The Mechanism of Antigenic Drift in Influenza Viruses: Analysis of Hong Kong (H3N2) Variants with Monoclonal Antibodies to the Hemagglutinin Molecule. Ann NY Acad Sci. 354:142-161.
Specific Reference
Govorkova, E.A., et al. (2006) Immunization with Reverse-Genetics–Produced H5N1 Influenza Vaccine Protects Ferrets against Homologous and Heterologous Challenge. J. Infect. Dis. 194:159–167. Hoffmann, E., et al. (2005) Role of Specific Hemagglutinin Amino Acids in the Immunogenicity and Protection of H5N1 Influenza Virus Vaccines. Proc. Natl. Acad. Sci. 102(36): 12915–12920. ML Reed, HL Yen, RM DuBois, OA Bridges, R Salomon, RG Webster, CJ Russell. (2009). Amino Acid Residues in the Fusion Peptide Pocket Regulate the pH of Activation of the H5N1 Influenza Virus Hemagglutinin Protein. J Virol. 2009 April; 83(8): 3568:3580. BJ Hanson, A Boon, APC Lim, A Webb, EE Ooi, RJ Webby. (2006). Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respiratory Research 2006, 7:126.
Log in to submit your product review.

IL-6 Human Recombinant Protein - 009-001-310

Product Type
Proteins and Peptides;
Reacts With
Human
Catalog Number
009-001-310

IL-4 Human Recombinant Protein - 009-001-B93

Product Type
Proteins and Peptides;
Reacts With
Human
Catalog Number
009-001-B93

IL-6 Mouse Recombinant Protein - 010-001-310

Product Type
Proteins and Peptides;
Reacts With
Mouse
Catalog Number
010-001-310

Anti-MOUSE IgG (H&L) (RABBIT) Antibody Peroxidase Conjugated - 610-4302

Product Type
Secondary Antibodies;
Applications
ELISA, WB, IHC
Catalog Number
610-4302

Product Label

 

Description
Unconjugated
Color
Conjugation Reference
Molecular Weight
Excitation Wavelength
Conjugation Chemistry